234 related articles for article (PubMed ID: 21045681)
1. Effects of niacin on atherosclerosis and vascular function.
Ruparelia N; Digby JE; Choudhury RP
Curr Opin Cardiol; 2011 Jan; 26(1):66-70. PubMed ID: 21045681
[TBL] [Abstract][Full Text] [Related]
2. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
5. GPR109A and vascular inflammation.
Chai JT; Digby JE; Choudhury RP
Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
[TBL] [Abstract][Full Text] [Related]
6. The role of niacin in lipid-lowering treatment: are we aiming too high?
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2013; 19(17):3094-106. PubMed ID: 23317400
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects.
Jiang Y; Jin M; Chen J; Yan J; Liu P; Yao M; Cai W; Pi R
Eur J Pharmacol; 2020 Feb; 868():172871. PubMed ID: 31846627
[TBL] [Abstract][Full Text] [Related]
8. Niacin: an old lipid drug in a new NAD
Romani M; Hofer DC; Katsyuba E; Auwerx J
J Lipid Res; 2019 Apr; 60(4):741-746. PubMed ID: 30782960
[TBL] [Abstract][Full Text] [Related]
9. Drugs targeting atherosclerosis: current and emerging approaches.
Manolopoulos VG; Tavridou A
Curr Pharm Des; 2009; 15(27):3091-3. PubMed ID: 19754383
[No Abstract] [Full Text] [Related]
10. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
Lukasova M; Hanson J; Tunaru S; Offermanns S
Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259
[TBL] [Abstract][Full Text] [Related]
11. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
12. Niacin: the evidence, clinical use, and future directions.
Villines TC; Kim AS; Gore RS; Taylor AJ
Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
[TBL] [Abstract][Full Text] [Related]
13. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
14. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
15. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
16. Niacin in cardiovascular disease: recent preclinical and clinical developments.
Digby JE; Ruparelia N; Choudhury RP
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):582-8. PubMed ID: 22207729
[TBL] [Abstract][Full Text] [Related]
17. Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor.
Ibrahim WW; Sayed RH; Kandil EA; Wadie W
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110583. PubMed ID: 35690118
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic acid: recent developments.
Kamanna VS; Vo A; Kashyap ML
Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
[TBL] [Abstract][Full Text] [Related]
19. Niacin: a long history, but a questionable future.
Ginsberg HN; Reyes-Soffer G
Curr Opin Lipidol; 2013 Dec; 24(6):475-9. PubMed ID: 24184940
[TBL] [Abstract][Full Text] [Related]
20. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
Goel H; Dunbar RL
Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
